Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications - DNA Repair in Cancer Therapy - page 113

26. Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J.
Formation and repair of cisplatin-induced adducts to DNA in
cultured normal and repair-deficient human fibroblasts. Cancer
Res 1988;

45. deLaat WL, Appeldoorn E, Jaspers NGJ, Hoeijmakers JHJ. DNA
structural elements required for ERCC1-XPF endonuclease
activity. J Biol Chem 1998; 42.

46. Sijbers AM, de Laat WL, Ariza RR, et al. Xeroderma pigmen-
tosum group F caused by a defect in a structure-specific DNA
repair endonuclease. Cell 1996;

(14):7835

273 e

62.
27. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR,
Masters JRW. DNA repair capacity and cisplatin sensitivity of
human testis tumour cells. Int J Cancer 1997;

(21):6058

48 e

22.
47. Enzlin JH, Scharer OD. The active site of the DNA repair
endonuclease XPF-ERCC1 forms a highly conserved nuclease
motif. EMBO J 2002;

(5):811

86 e

5.
28. Koberle B, Masters JRW, Hartley JA, Wood RD. Defective repair
of cisplatin-induced DNA damage caused by reduced XPA
protein in testicular germ cell tumours. Curr Biol 1999;

(5):551

70 e

53.
48. Tripsianes K, Folkers G, Ab E, et al. The structure of the human
ERCC1/XPF interaction domains reveals a complementary role
for the two proteins in nucleotide excision repair. Structure
2005;

21 (8):2045 e

9 (5):

6.
29. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Koberle B.
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in
testis tumor cell lines. Int J Cancer 2004;

273 e

58.
49. Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal
structure and DNA binding functions of ERCC1, a subunit of
the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl
Acad Sci USA 2005;

(12):1849

13 e

61.
30. Koberle B, Roginskaya V, Wood RD. XPA protein as a limiting
factor for nucleotide excision repair and UV sensitivity in
human cells. DNA Repair (Amst) 2006;

(3):352

110 e

8.
31. Usanova S, Piee-Staffa A, Sied U, et al. Cisplatin sensitivity of
testis tumour cells is due to deficiency in interstrand-crosslink
repair and low ERCC1-XPF expression. Mol Cancer 2010;

(5):641

5 e

41.
50. de Laat WL, Appeldoorn E, Sugasawa K, Weterings E,
Jaspers NGJ, Hoeijmakers JHJ. DNA-binding polarity of human
replication protein A positions nucleases in nucleotide excision
repair. Genes Devel 1998;

(32):11236

102 e

:248.
32. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross com-
plementing-group 1: gene expression and platinum resistance.
Int J Mol Med 2004;

9

609.
51. Tsodikov OV, Ivanov D, Orelli B, et al. Structural basis for the
recruitment of ERCC1-XPF to nucleotide excision repair
complexes by XPA. EMBO J 2007;

(16):2598

12 e

70.
33. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M,
Hamilton TC. Increased DNA repair as a mechanism of
acquired resistance to cis-diamminedichloroplatinum (II) in
human ovarian cancer cell lines. Cancer Res 1988;

(6):959

14 e

76.
52. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad
Sci USA 2002;

(22):4768

26 e

5.
53. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of
ERCC1 as a novel prognostic marker in advanced bladder
cancer patients receiving cisplatin-based chemotherapy. Ann
Oncol 2007;

(7):4592

99 e

6.
34. Lieber MR. The FEN-1 family of structure-specific nucleases in
eukaryotic DNA replication, recombination and repair. Bio-
essays 1997;

(20):5713

48 e

40.
35. Yang W. Pruning DNA: structure-specific endonucleases (XPF/
Rad1/Mus81). Structure 2003;

19 (3):233 e

8.
54. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1
expression predict outcome of patients with locally advanced
bladder cancer receiving adjuvant chemotherapy. Neoplasia
2010;

18 (3):522 e

6.
36. Brookman KW, Lamerdin JE, Thelen MP, et al. ERCC4 (XPF)
encodes a human nucleotide excision repair protein with
eukaryotic recombination homologs. Mol Cell Biol 1996;

(4):365

11 e

36.
55. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1
in non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med 2006;

12 (8):628 e

(11):

16

62.
37. Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution
of human excision nuclease with recombinant XPF- ERCC1
complex. J Biol Chem 1997;

6553

e

91.
56. Ricceri F, Guarrera S, Sacerdote C, et al. ERCC1 haplotypes
modify bladder cancer risk: a case-control study. DNA Repair
(Amst) 2010;

355 (10):983 e

7.
38. Al-Minawi AZ, Lee YF, Hakansson D, et al. The ERCC1/XPF
endonuclease is required for completion of homologous
recombination at DNA replication forks stalled by inter-strand
cross-links. Nucl Acids Res 2009;

272 (6):3833 e

200.
57. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment
response in advanced non-small cell lung cancer. Lung Cancer
2007;

(2):191

9 e

13.
39. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M,
Essigmann JM, Wood RD. Repair of an interstrand DNA cross-
link initiated by ERCC1-XPF repair/recombination nuclease.
J Biol Chem 2000;

(19):6400

37 e

8.
58. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide
excision repair in cisplatin-resistant ovarian cancer cells

(2):281

56 e

role

e

13.
59. Li QD, Yu JJ, Mu CJ, et al. Association between the level of
ERCC-1 expression and the repair of cisplatin-induced DNA
damage in human ovarian cancer

of ERCC1-XPF. Biochem Pharmacol 2000; 60 (9):1305 e

6.
40. Munoz P, Blanco R, Flores JM, Blasco MA. XPF nuclease-
dependent telomere loss and increased DNA damage in mice
overexpressing TRF2 result in premature aging and cancer. Nat
Genet 2005;

275 (34):26632 e

cells. Anticancer Res

52.
60. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. Clear cell
tumors have higher mRNA levels of ERCC1 and XPB than other
histological types of epithelial ovarian cancer. Clin Cancer Res
2003;

2000; (2A):645

20 e

71.
41. Niedernhofer LJ, Essers J, Weeda G, et al. The structure-specific
endonuclease Ercc1-Xpf is required for targeted gene replace-
ment in embryonic stem cells. EMBO J 2001;

(10):1063

37 e

9.
42. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-
specific endonuclease Ercc1-Xpf is required to resolve DNA
interstrand cross-link-induced double-strand breaks. Mol Cell
Biol 2004;

(22):6540

20 e

305.
61. Liu C, Zhou S, Begum S, et al. Increased expression and activity
of repair genes TDP1 and XPF in non-small cell lung cancer.
Lung Cancer 2007;

(14):5299

9 e

11.
62. Arora S, Kothandapani A, Tillison K, Kalman-Maltese V,
Patrick SM. Downregulation of XPF-ERCC1 enhances cisplatin
efficacy in cancer cells. DNA Repair (Amst) 2010;

55 (3):303 e

87.
43. Schiestl RH, Prakash S. RAD10, an excision repair gene of
Saccharomyces cerevisiae, is involved in the RAD1 pathway of
mitotic recombination. Mol Cell Biol 1990;

(13):5776

24 e

91.
44. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH,
de LT. ERCC1/XPF removes the 3' overhang from uncapped
telomeres and represses formation of telomeric DNA-contain-
ing double minute chromosomes. Mol Cell 2003;

(6):2485 53.

63. Chang IY, Kim MH, Kim HB, et al. Small interfering RNA-
induced suppression of ERCC1 enhances sensitivity of human
cancer cells to cisplatin. Biochem Biophys Res Commun 2005;

9 (7):745 e

10 e

(1):

327

12 (6):1489 e 98. 225 e 33.